Ultrasound Guided Renal Denervation shown to Decrease Ambulatory Blood Pressure in Patients with Resistant Hypertension: Results from the RADIANCE-HTN TRIO Trial
While renal denervation has been shown to improve blood pressure in patients with moderate hypertension, its effects on resistant hypertension have been more modest.... Read more.
Relationship Between Omega-3 Fatty Acid Levels And Major Adverse Cardiovascular Outcomes In Patients With High Cardiovascular Risk
KEY POINT: There is not enough evidence to state whether Omega-3 Fatty Acid levels are beneficial or harmful against major adverse cardiovascular events in patients... Read more.
Are ACE Inhibitors or Beta-Blockers Cardioprotective During Adjuvant Treatment for Early-Stage Breast Cancer?
New results were presented from the Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) trial at ACC 2021 on May 16 and published concurrently... Read more.
Rivaroxaban shown to lower future vascular events after peripheral revascularization: results from VOYAGER-PAD
Rivaroxaban should be considered as adjunctive therapy to aspirin alone in patients undergoing peripheral limb revascularization, authors of the VOYAGER-PAD trial... Read more.
Dapagliflozin in the Treatment of COVID-19: Insights from the DARE-19 Trial
SGLT-2 inhibitors have demonstrated efficacy in various cardiometabolic conditions, including heart failure, coronary artery disease, chronic kidney disease, and... Read more.
Tricuspid Valve Replacement with the Transcatheter Evoque Valve is Safe and Effective at 30 days
Transcatheter tricuspid valve replacement has become a feasible alternative to surgery in patients deemed to be at high risk of adverse events, and in the past decade,... Read more.
Real-World Data Supports Continued use of Transcatheter Left Atrial Appendage Occlusion
The WATCHMAN left atrial appendage occluder device has been widely accepted as an alternative to oral anticoagulation for stroke prevention in patients with underlying... Read more.
Apixaban Associated with Fewer Subclinical Valve Thrombosis Events: Results from the ATLANTIS 4D-CT Substudy
Subclinical valve thrombosis after transcatheter aortic valve intervention (TAVI) has emerged as a challenge to the standardization of antithrombotic therapy after... Read more.
Apixaban not Superior to Standard of Care after TAVR in ATLANTIS
The administration of apixaban monotherapy after transcatheter aortic valve replacement is not superior to the standard of the care antithrombotic treatment, results... Read more.
Prospective ARNI Versus Ace Inhibitor Trial to Determine Superiority In Reducing Heart Failure Events After Myocardial Infarction (PARADISE-MI)
KEY POINTS Sacubitril/valsartan did not provide a lower rate of cardiovascular death, heart failure hospitalization, or outpatient development of heart failure when... Read more.